BMC Pharmacology and Toxicology

Table 4 Prevalence of anaemia according to selected risk factors among HIV infected pregnant women receiving co-trimoxazole prophylaxis (N = 420)

From: Prevalence of malaria and anaemia among HIV infected pregnant women receiving co-trimoxazole prophylaxis in Tanzania: a cross sectional study in Kinondoni Municipality

Univariate analysis				Multivariate analysis
Characteristics	n	Prevalence of anaemia n (%)	P-value	AOR	95% CI	P-value
*Malaria infection*
Yes	19	18 (94.7)		10.363	1.329-80.798	0.026
No (reference)	401	209 (52.1)	0.0001^a	1
*History of malaria illness*
Yes	107	76 (71)		1.746	1.005-3.033	0.048
No (reference)	313	151 (48.2)	0.0001^a	1
*WHO clinical stage*
Stage I (reference)	338	165 (48.8)		1
Stage II	43	32 (74.4)		3.076	1.458-6.491	0.003
Stage III-IV	37	30 (76.9)	0.0001^a	2.653	1.184-5.945	0.018
CD4 count (cells/μL)*
≥500	104	48 (46.2)		-
350-499	85	45 (52.9)		-
200-349	96	62 (64.6)		⁻
<200	59	42 (71.2)	0.005^a	-
*Pregnancy trimester*
1st trimester	20	9 (45)		-
2nd trimester	206	107 (51.9)		-
3rd trimester	194	111 (57.2)	0.404^a	-
*Gravidity*
Primigravidae	139	72 (51.8)		-
Secundigravidae	148	83 (56.1)		-
Multigravidae	133	72 (54.1)	0.767^a	-
*ITN use*
Yes	380	201 (52.9)		-
No	40	26 (65)	0.144^a	-
*ART category*
ARV Prophylaxis	288	146 (50.7)		-
Life-long ART	132	81 (61.4)	0.142^a	-
*Duration of AZT use (months)*
<3	162	93 (57.4)		-
3-5.9	168	92 (54.8)		⁻
≥6	90	42 (46.7)	0.253^a	-
*Iron supplements*
Yes	338	185 (54.7)		-
No	82	42 (51.2)	0.567^a	-
*Use of de-worming drug*
Yes	327	171 (52.3)		-
No	93	56 (60.2)	0.176^a	-
*Adherence to co-trimoxazole*
Good (reference)	208	92 (44.2)		1
Average	80	47 (58.8)		1.478	0.848-2.578	0.168
Poor	132	88(66.7)	0.0001^a	1.752	1.03-2.979	0.039

^aCalculated by Pearson Chi Square, *Results of CD4 Count were available for only 344 subjects out of 420 (81.9%).

Back to article page

ISSN: 2050-6511

Contact us

Submission enquiries: bmcpharmacologyandtoxicology@biomedcentral.com
General enquiries: ORSupport@springernature.com